Answers are grounded in this paper and cite their sources.
In comparison with antisense oligonucleotides and small interfering RNAs, Dzs do not usually show off-target effects due to their high specificity and lack of immunogenicity in vivo. As more results of clinical trials carried out so far are gradually becoming available, Dzs may turn out to be safe and well-tolerated therapeutics in humans. Therefore, there is a good chance that we may witness a deoxyribozyme drug reaching the clinic in the near future.
No takes yet. Share an insight, caveat, or question.
Фокина et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: